Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study

Journal of Human Hypertension volume 37, pages 345–353 (2023)Cite this article

Subjects

Abstract

Treatment resistant hypertension (TRH) appears of particular relevance in patients with chronic kidney disease (CKD). However, causes and consequences of TRH in CKD patients remain incompletely understood. Therefore, we analyzed the prevalence of apparent TRH (aTRH), and phenotypic characteristics and prognosis associated with aTRH among participants of the German Chronic Kidney Disease (GCKD) study. As insufficient medication adherence has been shown to be a frequent cause of pseudoresistance, we also assessed treatment adherence. Study participants were classified as having aTRH, controlled hypertension and uncontrolled hypertension based on study visit blood pressure and self-reported medication intake. Drug adherence was assessed by comparing self-reported antihypertensive medication with detectable urinary drug metabolites measured by mass spectroscopy. Out of 4901 individuals included in this study, 38% were classified as having aTRH. Male sex, older age, lower estimated glomerular filtration rate (eGFR), higher body mass index (BMI), higher urine albumin-to-creatinine ratio (UACR) and presence of diabetes mellitus were independently associated with higher prevalence of aTRH in a multivariable adjusted regression model. Patients classified as aTRH had higher risk for major adverse cardiovascular events and worsening of kidney disease compared to patients with no aTRH after multivariate adjustment for potential confounders. There was a high agreement between self-reported medication and detectable urinary drug metabolites. In conclusion, in a cohort of Caucasian patients with moderately severe CKD, aTRH was highly prevalent and, in most cases, likely not caused by low medication adherence. Furthermore, aTRH was linked to cardio-renal endpoints, emphasizing the need for improved management.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Comparison of the proportion of self-reported drug use across patient groups.
Fig. 2: Visual comparison of cumulative incidence rates across groups for selected time-to-event endpoints.
Fig. 3: Hazard ratios for comparison between patients classified as aTRH vs. patients classified as non-aTRH patients.
Fig. 4: Comparison of Cohen’s kappa (agreement between self-reported and metabolite-detectable medication) across patients with controlled, uncontrolled hypertension and patients classified as aTRH.

Similar content being viewed by others

Data availability

GCKD data is not publicly available. The code for this analysis is available from the corresponding author on reasonable request.

References

  1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.

    Article  Google Scholar 

  2. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386:1588–98.

    Article  PubMed  Google Scholar 

  3. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, et al. Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD. Clin J Am Soc Nephrol. 2013;8:1583–90.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension 2016;67:387–96.

    Article  CAS  PubMed  Google Scholar 

  5. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.

    Article  CAS  PubMed  Google Scholar 

  6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510–26.

    Article  PubMed  Google Scholar 

  7. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association. Hypertension 2018;72:e53–e90.

    Article  CAS  PubMed  Google Scholar 

  8. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 2019;73:424–31.

    Article  CAS  PubMed  Google Scholar 

  9. de Beus E, Bots ML, van Zuilen AD, Wetzels JF, Blankestijn PJ, Group MS. Prevalence of apparent therapy-resistant hypertension and its effect on outcome in patients with chronic kidney disease. Hypertension 2015;66:998–1005.

    Article  PubMed  Google Scholar 

  10. Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertension. 2015;29:213–8.

    Article  CAS  Google Scholar 

  11. Schneider MP, Hilgers KF, Schmid M, Hubner S, Nadal J, Seitz D, et al. Blood pressure control in chronic kidney disease: a cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. PloS one. 2018;13:e0202604.

    Article  PubMed  PubMed Central  Google Scholar 

  12. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61:2461–7.

    Article  PubMed  Google Scholar 

  13. Eckardt KU, Bärthlein B, Baid-Agrawal S, Beck A, Busch M, Eitner F, et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol, Dialysis, Transplant: Off Publ Eur Dialysis Transpl Assoc - Eur Ren Assoc. 2012;27:1454–60.

    Article  CAS  Google Scholar 

  14. Titze S, Schmid M, Köttgen A, Busch M, Floege J, Wanner C, et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol, Dialysis, Transplant: Off Publ Eur Dialysis Transpl Assoc - Eur Ren Assoc. 2015;30:441–51.

    Article  Google Scholar 

  15. Evans AM, Bridgewater BR, Liu Q, Mitchell MW, Robinson RJ, Dai H, et al. High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics. Metabolomics 2014;04:132.

    Google Scholar 

  16. Schlosser P, Li Y, Sekula P, Raffler J, Grundner-Culemann F, Pietzner M, et al. Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans. Nat Genet. 2020;52:167–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kotsis F, Schultheiss U, Wuttke M, Schlosser P, Mielke J, Becker MS, et al. Self-reported medication use and urinary drug metabolites in the German chronic kidney disease (GCKD) study. J of the Am Soc of Nephrol. 2021;32:2315–29.

    Article  Google Scholar 

  18. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. application in1H NMR metabonomics. Anal Chem. 2006;78:4281–90.

    Article  CAS  PubMed  Google Scholar 

  19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Ann Stat. 1988;16:1141–54.

    Article  Google Scholar 

  20. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

    Article  Google Scholar 

  21. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239–41.

    Article  Google Scholar 

  22. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276–82.

    Article  PubMed  Google Scholar 

  23. R Core Team. R: A language and environment for statistical computing. Vienna. Austria: R foundation for statistical computing.; 2021. https://www.R-project.org/

    Google Scholar 

  24. Thernau T. A package for survival analysis in R. R package version 3.1-12 2020. https://CRAN.R-project.org/package=survival.

  25. Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.12. 2019. https://CRAN.R-project.org/package=pheatmap.

  26. Wickham H. tidyverse: Easily Install and Load the “Tidyverse”. R package version 1.2.1. 2017. https://CRAN.R-project.org/package=tidyverse.

  27. Kassambara A, Kosinski M, Biecek P survminer: Drawing Survival Curves using “ggplot2”. R package version 0.4.6. 2019. https://CRAN.R-project.org/package=survminer.

  28. Gray B cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2.-10. 2020. https://CRAN.R-project.org/package=cmprsk.

  29. Revelle W. psych: Procedures for Personality and Psychological Research. Evanston, Illinois, USA: Northwerstern University; 2019. https://CRAN.R-project.org/package=psych

    Google Scholar 

  30. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biometrical J. 2008;50:346–63.

    Article  Google Scholar 

  31. Viazzi F, Greco E, Ceriello A, Fioretto P, Giorda C, Guida P, et al. Apparent treatment resistant hypertension, blood pressure control and the progression of chronic kidney disease in patients with Type 2 diabetes. Kidney blood Press Res. 2018;43:422–38.

    Article  PubMed  Google Scholar 

  32. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635–42.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Akinyelure OP, Sakhuja S, Colvin CL, Clark D 3rd, Jaeger BC, Hardy ST, et al. Cardiovascular health and transition from controlled blood pressure to apparent treatment resistant hypertension: The Jackson Heart Study and the REGARDS Study. Hypertension 2020;76:1953–61.

    Article  CAS  PubMed  Google Scholar 

  34. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88:622–32.

    Article  PubMed  PubMed Central  Google Scholar 

  35. van der Sande NGC, de Beus E, Bots ML, Voskuil M, Blankestijn PJ, Visseren F, et al. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease. J Hypertens. 2018;36:143–50.

    Article  PubMed  Google Scholar 

  36. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32:635–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Maiolino G, Azzolini M, Rossi GP. Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines! Front cardiovascular Med. 2015;2:3.

    Article  Google Scholar 

  39. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766–74.

    Article  CAS  PubMed  Google Scholar 

  40. Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, et al. Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. J Am Heart Assoc. 2016;5:e002343.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014;100:855–61.

    Article  CAS  PubMed  Google Scholar 

  42. Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Stork S, et al. Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. Hypertension 2018;72:929–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful for the willingness of the patients to participate in the GCKD study. The enormous effort of the study personnel of the various regional centers is highly appreciated. We thank the large number of nephrologists who provide routine care for the patients and collaborate with the GCKD study. The work of AK was supported by grant 3598/5-1 from the German Research Foundation (DFG). FK was supported by the Else Kroener Fresenius Foundation (NAKSYS) and by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (grant 01ZX1912B). The GCKD study was/is funded by grants from the Federal Ministry of Education and Research (BMBF, grant number 01ER0804) and the KfH Foundation for Preventive Medicine and corporate sponsors.

Author information

Authors and Affiliations

  1. Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany

    Johanna Mielke, Holger Trucks-Jansen, Claudia Schurmann & Daniel F. Freitag

  2. Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center—University of Freiburg, Freiburg, Germany

    Fruzsina Kotsis & Anna Köttgen

  3. Department of Medicine IV – Nephrology and Primary Care, Faculty of Medicine and Medical Center – University of Freiburg, Freiburg, Germany

    Fruzsina Kotsis

  4. Department of Nephrology and Hypertension, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Markus P. Schneider & Kai-Uwe Eckardt

  5. Department of Nephrology and Hypertension, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany

    Markus P. Schneider

  6. Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Kai-Uwe Eckardt

  7. Bayer AG, Research & Early Development, Precision Nephrology, Division Pharmaceuticals, Wuppertal, Germany

    Frank Eitner & Michael S. Becker

  8. Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center—University of Freiburg, Freiburg, Germany

    Fruzsina Kotsis & Anna Köttgen

  9. Department of Medicine IV – Nephrology and Primary Care, Faculty of Medicine and Medical Center – University of Freiburg, Freiburg, Germany

    Fruzsina Kotsis

  10. Department of Nephrology and Hypertension, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Markus P. Schneider & Kai-Uwe Eckardt

  11. Department of Nephrology and Hypertension, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany

    Markus P. Schneider

  12. Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Kai-Uwe Eckardt

Authors
  1. Johanna Mielke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holger Trucks-Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia Schurmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fruzsina Kotsis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Köttgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus P. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kai-Uwe Eckardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel F. Freitag
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Frank Eitner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael S. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

GCKD Investigators

  • Fruzsina Kotsis
  • , Anna Köttgen
  • , Markus P. Schneider
  •  & Kai-Uwe Eckardt

Contributions

Design of this study: JM, MSB. Recruitment, management and conduct of cohort study: FK, AK, MPS, KUE. Bioinformatics and statistical analysis: JM, CS. Wrote the manuscript: JM, MSB, HT-J. Edited, critically read and approved the manuscript: JM, HT-J, CS, FK, AK, MPS, KUE, DFF, FE, MSB.

Corresponding author

Correspondence to Michael S. Becker.

Ethics declarations

Competing interests

JM, HT-J, CS, DFF, FE, MSB are employees from Bayer AG. For the remaining authors no conflicts of interest were declared.

Ethical approval

The study was approved by the local ethics committee, registered in the German national registry for clinical studies (DRKS00003971) and was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice. Informed consent was obtained from all patients prior to enrollment.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mielke, J., Trucks-Jansen, H., Schurmann, C. et al. Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study. J Hum Hypertens 37, 345–353 (2023). https://doi.org/10.1038/s41371-022-00701-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-022-00701-0

Search

Advanced search

Quick links